As small RNAs are considered as biopharmaceuticals, for example to treat heart dysfunctions or cancers [73], their effectivity in treating RTT organoids might render them suitable to also treat features in other brain pathologies, including FOXG1 syndrome. The gene discussed is FOXG1; the disease is Down syndrome.